.jpg)
Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.
